DEVELOPMENT, FORMULATION, AND EVALUATION OF SODIUM ALGINATE-G-POLY (ACRYL AMIDE-CO-ACRYLIC ACID/CLOISTE-30B)/AGNPs HYDROGEL COMPOSITES AND THEIR APPLICATIONS IN PACLITAXEL DRUG DELIVERY AND ANTICANCER ACTIVITY

Abstract

Objective: The objective of this study was to develop, formulate and evaluate the sodium alginate grafted poly (acrylamide-co-acrylic acid/cloisite-30B/silver nanoparticle hydrogel composites (SA-PAAm-PAAc/C30B/AgNPs) with varying weight percentage (wt %) of cloisite-30B clay for paclitaxel targeted delivery and anticancer activity.
 Methods: Polymer hydrogel composites of different wt % of cloisite-30B modified clay dispersed sodium alginate (SA) grafted polyacrylamide-co-polyacrylic acid were prepared via in situ free radical initiation polymerization reaction technique. In vitro release of paclitaxel (PT) anticancer drug and anticancer studies were performed. The formulations were further evaluated for swelling, drug encapsulation, drug delivery, anticancer activity study, Fourier transforms infrared spectroscopy (FT-IR), thermogravimetric (TGA), differential scanning calorimeter (DSC) and x-ray diffraction (XRD) characterizations.
 Results: FT-IR spectroscopy of various composite hydrogel formulations displayed good compatibility between sodium alginate, polyacrylamide, and polyacrylic acid polymers. The thermal study reveals that the formulations with clay (C30B) and AgNPs in hydrogel composites exhibit good thermal stability and less % of weight loss (wt. loss) compared to pure formulations. Further, the highest encapsulation efficiency was shown by the formulation S0-0+D (72.66±5.92%) and least encapsulation efficiency was shown by S75Ag+D (41.33±3.12%) compared to rest of the formulations and S50Ag+D and S75Ag+D samples exhibits relatively slightly higher and sustained cumulative release rate of PT drug at an average rate of 80±9 % within 72 h and also shows relatively better anticancer activity compared to other formulations.
 Conclusion: Formulations S50Ag+D and S75Ag+Dwere found to be best formulations with a higher cumulative percentage of PT drug release and showed better anticancer activity